The FINANCIAL — Synairgen plc, the respiratory drug discovery and development company which originated from research at the University of Southampton, is pleased to announce positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients. Researchers have announced the results of an initial trial which found the odds of Covid-19 patients not needing ventilation, or dying, while being treated in hospital were 79% better among those given SNG001 compared with those given a placebo. Shares of Synairgen soared more than 450% in London on Monday after the company reported positive early results from a…
Read More »
The FINANCIAL — Synairgen plc, the respiratory drug discovery and development company which originated from research at the University of Southampton, is pleased to announce positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients. Researchers have announced the results of an initial trial which found the odds…
You might be interested in
Older people are likely to be vaccinated regardless of party affiliation. New research from the University of Georgia suggests age and…
SARS-CoV-2 infection can trigger the production of immune molecules that damage cells lining blood vessels in the brain, causing platelets…
The FINANCIAL — COVID-19 was the third leading cause of death in the United States between March 2020 and October…
In the UK, there were 346 deaths involving COVID-19 registered in the week ending 24 June 2022, an increase from…